Biosimilars Market Report 2026

The biosimilars market size has grown rapidly in recent years. It will grow from $21.85 billion in 2025 to $25.53 billion in 2026 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to rising prevalence of chronic and autoimmune diseases, high cost of originator biologics, increasing demand for cost-effective therapies, advancements in biopharmaceutical R&D, growing healthcare infrastructure in emerging economies.

The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $48.52 billion in 2030 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to patent expirations of blockbuster biologics, increasing adoption of biosimilars in oncology and autoimmune therapy, government incentives and supportive policies, expansion of manufacturing capabilities in asia-pacific, growing partnerships between biopharma companies and contract manufacturing organizations. Major trends in the forecast period include personalized biosimilar development, cost-effective biologics manufacturing, regulatory harmonization and compliance, expansion of emerging markets for biosimilars, strategic collaborations and partnerships.

The rising healthcare expenditures are anticipated to drive the growth of the biosimilars market in the coming years. Healthcare expenditures encompass the total spending on healthcare goods and services within a population or healthcare system. The biosimilars market contributes to reducing healthcare costs by providing more affordable alternatives to expensive biologic drugs, thereby lowering treatment expenses for patients and healthcare systems. For example, in March 2024, according to the Health Foundation, a UK-based independent charity and think tank, total health expenditures in England for 2022/23 reached £182 billion ($196.78 billion). While planned health spending is projected to rise to £192 billion ($207.59 billion) in 2024/25, inflation will result in only a modest real-term increase of 0.6% compared to the 2023/24 fiscal year. Consequently, rising healthcare expenditures are supporting the expansion of the biosimilars market.

Key players in the biosimilars market are focusing on developing innovative products to secure a competitive advantage. FYLNETRA is a leukocyte growth factor indicated to reduce the risk of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer therapies associated with a clinically significant incidence of febrile neutropenia. For instance, in May 2023, Amneal Pharmaceuticals Inc., a US-based pharmaceutical company, commercially launched FYLNETRA (pegfilgrastim-pbbk), a biosimilar referencing Neulasta, in a pre-filled single-dose syringe. FYLNETRA treats neutropenia, a condition of low neutrophils - white blood cells essential for fighting infection - commonly observed in chemotherapy patients.

In January 2024, Sandoz, a Switzerland-based pharmaceutical company, acquired the CIMERLI (ranibizumab) biosimilar business from Coherus BioSciences for an undisclosed sum. Through this acquisition, Sandoz aims to enhance its ophthalmic biosimilar portfolio and expand its commercial footprint in the U.S. market. Coherus BioSciences is a US-based biotechnology company engaged in developing and marketing biosimilars and innovative biologic therapies.

Major companies operating in the biosimilars market are Amgen, Novartis AG, Samsung Bioepis Co. Ltd., Viatris, Celltrion Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd, Abbott India Limited, Wuxi Biologics, Shanghai Henlius Biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

North America was the largest region in the global biosimilars market in 2025. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the biosimilars market by increasing the cost of raw materials, bioprocessing equipment, and active pharmaceutical ingredients, leading to higher production costs and supply chain disruptions. The market segments most affected include monoclonal antibodies and insulin biosimilars, particularly in regions like north america and europe, which rely on imported biologics components. While tariffs have posed challenges, they have also encouraged domestic manufacturing and local production strategies, potentially strengthening regional supply resilience and fostering innovation in cost-effective biosimilar development.

The biosimilars market research report is one of a series of new reports that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biosimilars are medications derived from living organisms, produced using various methods and slightly different materials. Their complexity, high production costs, and large molecular structures make them fundamentally different from generic drugs.

The main types of biosimilars include human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys that stimulates the production and maintenance of red blood cells. Biosimilar products include recombinant non-glycosylated proteins and recombinant glycosylated proteins, used to treat oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and other medical conditions.

The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.